NTV Asset Management LLC decreased its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 0.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,833 shares of the company’s stock after selling 87 shares during the quarter. Eli Lilly and Company makes up 3.3% of NTV Asset Management LLC’s holdings, making the stock its 4th largest holding. NTV Asset Management LLC’s holdings in Eli Lilly and Company were worth $18,681,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in LLY. Wellington Management Group LLP increased its holdings in Eli Lilly and Company by 1.6% during the first quarter. Wellington Management Group LLP now owns 20,324,267 shares of the company’s stock valued at $6,979,760,000 after buying an additional 314,349 shares during the period. Bank Julius Baer & Co. Ltd Zurich increased its holdings in Eli Lilly and Company by 533,336.4% during the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 19,059,681 shares of the company’s stock valued at $8,938,609,000 after buying an additional 19,056,108 shares during the period. Geode Capital Management LLC increased its holdings in Eli Lilly and Company by 1.1% during the first quarter. Geode Capital Management LLC now owns 14,867,424 shares of the company’s stock valued at $5,094,159,000 after buying an additional 159,964 shares during the period. Morgan Stanley increased its holdings in Eli Lilly and Company by 44.1% during the fourth quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock valued at $4,411,740,000 after buying an additional 3,691,436 shares during the period. Finally, Norges Bank purchased a new position in Eli Lilly and Company during the fourth quarter valued at approximately $3,416,206,000. Institutional investors own 81.38% of the company’s stock.
Insider Activity at Eli Lilly and Company
In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 37,660 shares of Eli Lilly and Company stock in a transaction on Monday, August 28th. The shares were sold at an average price of $546,751.75, for a total value of $20,590,670,905.00. Following the completion of the transaction, the insider now owns 100,275,279 shares of the company’s stock, valued at $54,825,684,274,988.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, major shareholder Lilly Endowment Inc sold 37,660 shares of the business’s stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $546,751.75, for a total transaction of $20,590,670,905.00. Following the completion of the sale, the insider now owns 100,275,279 shares of the company’s stock, valued at $54,825,684,274,988.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Alonzo Weems sold 1,148 shares of the business’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $590.98, for a total transaction of $678,445.04. Following the sale, the executive vice president now directly owns 7,760 shares of the company’s stock, valued at approximately $4,586,004.80. The disclosure for this sale can be found here. Insiders sold 907,655 shares of company stock worth $21,078,714,805 over the last three months. Company insiders own 0.13% of the company’s stock.
Analysts Set New Price Targets
Several brokerages recently issued reports on LLY. Bank of America lifted their price objective on shares of Eli Lilly and Company from $600.00 to $700.00 in a report on Friday, October 6th. StockNews.com lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Wednesday, October 18th. Royal Bank of Canada lifted their price target on shares of Eli Lilly and Company from $490.00 to $580.00 and gave the stock an “outperform” rating in a report on Tuesday, August 8th. Argus lifted their price target on shares of Eli Lilly and Company from $470.00 to $620.00 and gave the stock a “buy” rating in a report on Tuesday, September 5th. Finally, HSBC began coverage on shares of Eli Lilly and Company in a report on Friday, July 14th. They issued a “buy” rating and a $560.00 price target on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and nineteen have assigned a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $549.30.
Get Our Latest Report on Eli Lilly and Company
Eli Lilly and Company Stock Performance
NYSE LLY traded down $1.63 on Monday, reaching $583.01. 937,504 shares of the company’s stock traded hands, compared to its average volume of 3,031,346. The firm has a market cap of $553.45 billion, a price-to-earnings ratio of 81.18, a P/E/G ratio of 3.45 and a beta of 0.33. The stock has a 50 day moving average price of $565.42 and a 200-day moving average price of $481.27. Eli Lilly and Company has a fifty-two week low of $309.20 and a fifty-two week high of $629.97. The company has a debt-to-equity ratio of 1.63, a quick ratio of 0.87 and a current ratio of 1.13.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its earnings results on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.98 by $0.13. The company had revenue of $8.31 billion during the quarter, compared to the consensus estimate of $7.58 billion. Eli Lilly and Company had a net margin of 22.01% and a return on equity of 65.00%. The firm’s quarterly revenue was up 28.1% on a year-over-year basis. During the same period in the previous year, the firm posted $1.25 earnings per share. Equities research analysts predict that Eli Lilly and Company will post 6.65 EPS for the current fiscal year.
Eli Lilly and Company Company Profile
(Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
Featured Articles
Receive News & Ratings for Eli Lilly and Company Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eli Lilly and Company and related companies with MarketBeat.com’s FREE daily email newsletter.
